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Abstract
Background: Declining serum concentrations of 25-hydroxyvitamin D seen in the fall and winter as distance increases from
the equator may be a factor in the seasonal increased prevalence of influenza and other viral infections. This study was done
to determine if serum 25-hydroxyvitamin D concentrations correlated with the incidence of acute viral respiratory tract
infections.
Methodology/Findings: In this prospective cohort study serial monthly concentrations of 25-hydroxyvitamin D were
measured over the fall and winter 2009–2010 in 198 healthy adults, blinded to the nature of the substance being measured.
The participants were evaluated for the development of any acute respiratory tract infections by investigators blinded to
the 25-hydroxyvitamin D concentrations. The incidence of infection in participants with different concentrations of vitamin
D was determined. One hundred ninety-five (98.5%) of the enrolled participants completed the study. Light skin
pigmentation, lean body mass, and supplementation with vitamin D were found to correlate with higher concentrations of
25-hydroxyvitamin D. Concentrations of 38 ng/ml or more were associated with a significant (p,0.0001) two-fold reduction
in the risk of developing acute respiratory tract infections and with a marked reduction in the percentages of days ill.
Conclusions/Significance: Maintenance of a 25-hydroxyvitamin D serum concentration of 38 ng/ml or higher should
significantly reduce the incidence of acute viral respiratory tract infections and the burden of illness caused thereby, at least
during the fall and winter in temperate zones. The findings of the present study provide direction for and call for future
interventional studies examining the efficacy of vitamin D supplementation in reducing the incidence and severity of
specific viral infections, including influenza, in the general population and in subpopulations with lower 25-hydroxyvitamin
D concentrations, such as pregnant women, dark skinned individuals, and the obese.
Citation: Sabetta JR, DePetrillo P, Cipriani RJ, Smardin J, Burns LA, et al. (2010) Serum 25-Hydroxyvitamin D and the Incidence of Acute Viral Respiratory Tract
Infections in Healthy Adults. PLoS ONE 5(6): e11088. doi:10.1371/journal.pone.0011088
Editor: Delia Goletti, National Institute for Infectious Diseases L. Spallanzani, Italy
Received April 15, 2010; Accepted May 19, 2010; Published June 14, 2010
Copyright:  2010 Sabetta et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by a private grant from Jean and David Wallace of Greenwich, Connecticut to the Section of Infectious Diseases, Greenwich
Hospital. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The work on this study by
the investigators was without any compensation, with all funding used for laboratory analysis and data recording.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: jsabettamd@yahoo.com
Introduction
There are seasonal variations in the incidences of viral respiratory
tract infections, such as those caused by influenza [1], respiratory
syncytial virus [2], and rhinovirus [3]. Explanations for the
seasonality of infections have considered the effects of environmental
factors on the survival and transmission of the pathogens [4,5] as well
as on the behavior and susceptibility of the hosts [6].
Indoor crowding is commonly thought to contribute to the
influenza epidemics seen each winter in temperate zones.
However, influenza epidemics do not occur in the summer in
crowded workplaces or other gatherings, despite the presence of
the virus and a multitude of nonimmune persons [6,7]. Moreover,
influenza epidemics occur simultaneously at the same latitudes
across the globe; this was the case even in times when
transportation methods did not allow contact between persons
over many degrees of longitude over a period of a few weeks [8].
There are well-documented seasonal variations in 25-hydro-
xyvitamin D (vitamin D) concentrations [9-11] and documented
correlations between those concentrations and latitudes of
residence [12,13].
Vitamin D has known effects on the immune system. The
production of the antimicrobial peptides cathelicidin by macro-
phages and b-defensin by endothelial cells is upregulated by
vitamin D [14,15]. These peptides may be involved in the direct
inactivation of viruses [16,17]. Vitamin D may modulate the
production of cytokines, suppressing inflammation [18], and,
thereby, reduce the severity of viral pneumonia [19].
The association between vitamin D deficiency and susceptibility
to infections of the respiratory tract has been suggested for many
years, but has not been definitively proven. Children with
nutritional rickets developed rachitic lung due to infections of
the respiratory tract [20,21]. Cod liver oil, rich in vitamin D, was
used to treat tuberculosis [22]. Epidemiologic studies have
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incidence of respiratory infections [23,24], including influenza
[25].
There have been no prospective, observational studies following
adult women and men with known vitamin D concentrations for
the development of acute viral respiratory tract infections. Since it
is unknown if an acute infection could transiently alter the 25-
hydroxyvitamin D concentration and concentrations would be
expected to decline over the fall and winter as latitude increases
from the equator, serial serum concentrations would have to be
obtained in a prospective study done in a temperate zone.
This study was undertaken to determine if there is any
correlation between the incidence of acute viral respiratory tract
infections and serum vitamin D concentrations as measured
monthly from September 20, 2009 to January 10, 2010 in healthy
adults living and/or working in or near Greenwich, CT, USA
(latitude 41.038N, longitude 73.614W).
Methods
Participants
All participants signed informed consent approved by the
Greenwich Hospital Institutional Review Board. Healthy adults,
contacted through formal and informal presentations, were asked
to volunteer to participate in this study. Exclusion criteria were
any chronic pulmonary, cardiac, renal, hepatic, hematologic,
neurologic, neuromuscular, or metabolic disorders (including
diabetes mellitus); immunosuppression; pregnancy; and/or high
dose aspirin therapy. Participants were not excluded if on thyroid
or estrogen replacement therapy, oral contraceptives, or if they
had mild seasonal allergies.
Participants agreed to donate one tube (7.5 cc) of blood
monthly, starting in the third week of September 2009, for 4–5
months, depending on an interim analysis after the third blood
draw. The participants were unaware of the nature of the
substance being measured; they also understood they would be
told the substance and their concentrations at the end of the study
and that this data might be of benefit to them for health reasons
unrelated to the study. The participants were asked to report any
evidence of an acute respiratory tract infection (rhinorrhea, sore
throat, and/or cough with or without fever, chills, myalgias,
arthralgias), in which case they would be evaluated without charge
at the study site.
Determination of 25-hydroxyvitamin D concentrations
After obtained, sera were refrigerated and assayed within 4–
48 hours in the Clinical Laboratory of Greenwich Hospital.
Concentrations of 25-hydroxyvitamin D were measured in
duplicate by a chemiluminescence immunoassay (LiaisonH) [26].
The first concentrations were drawn from September 20–28,
2009, and then monthly thereafter. The investigators on site were
blinded to the coded results, which were sent to the offsite
investigator (PDP) who was not involved in clinical assessment.
Clinical evaluation
Participants reporting any symptoms were seen the same day at
the study site by one of the two board-certified Infectious Diseases
investigators (JRS, RJC). Participants were interviewed, examined,
and, if felt to have an acute respiratory tract infection, had a
nasopharyngeal swab obtained for virology studies and bacterial
cultures if a bacterial infection was suspected. The participants
kept a diary of symptoms and were called every 1–3 days during
the illness to review any signs or symptoms until asymptomatic.
The duration of each symptom, the total illness duration, and any
antimicrobials administered were recorded in the case report
forms.
Between each monthly visit for 25-hydroxyvitamin D determi-
nations, all of the participants were reminded every 10 days to
report any illness. At each visit after the first, a clinical assessment
was made by both of the Infectious Diseases investigators to
determine if an illness being retrospectively reported by a
participant appeared to have been an acute viral respiratory tract
infection. In that case, an illness diary was completed, but no
virology studies performed. At each monthly visit records were
made for each participant regarding medications, herbals,
supplements, vitamins, receipt of seasonal and/or 2009 H1N1
vaccine. At the first visit, the skin pigmentation of each participant
was determined to be light (white-yellow), intermediate (tan-light
brown), or dark (brown-black); and, the following were recorded:
age, sex, height, weight, occupation, and contact information.
All data was entered into a secure web-accessible on-line
database (MARVI) as well as into paper case report forms for
back-up and quality verification purposes.
Virology studies
All participants presenting with acute symptoms of a respiratory
tract infection had a nasopharyngeal swab obtained and placed in
viral transport media (M4, Remel, Lenexa, KS). These specimens
were tested within 24 hours of collection at the Clinical Virology
Laboratory at the Yale New Haven Hospital by cytospin-
enhanced direct immunofluorescence (DFA) for adenovirus,
parainfluenza types 1,2,3, respiratory syncytial virus, and influenza
A and B (SimulFlour Respiratory Virus Screen, Light Diagnostics,
Temecula, CA) [27–29]. At the end of the study, DFA-negative
specimens that had been frozen at 270uC were assayed by RT-
PCR for the predominant viruses known to be circulating during
the study period and either not included in the DFA panel
(rhinovirus and human metapneumovirus) or suboptomally
detected (2009 H1N1 influenza) [30–32].
Classification of illness
All ill participants were determined to either have a bacterial
infection (e.g., streptococcal pharyngitis) or an acute viral
respiratory tract infection, the latter of which were subclassified
as either (1) an afebrile viral respiratory tract infection; (2) an
influenza-like illness (ILI) with temperature .100uF, cough and/
or sore throat in absence of a known cause; or, (3) a laboratory-
confirmed viral infection.
Bacterial infections were not evaluated in this study and were
excluded from the analysis.
Statistical Analyses
Assuming an overall incidence of viral respiratory tract
infections of 0.15 for the population over the time of study and
a laboratory measurement coefficient of variation of 10% for
serum vitamin D called for an enrollment of at least168
participants to achieve a Type I error of 0.05 and a Type II
error of 0.2 if the odds ratio between the two groups for an event
was $0.5 [33].
First, the initial serum 25-hydroxyvitamin D concentrations
were examined with respect to the onset of respiratory tract viral
infections seen over the entire study period. A non-linear
pharmacodynamic concentration-response model was construct-
ed, with parameters estimated by minimizing the log likelihood.
Several families of sigmoid concentration-response model struc-
tures relating serum 25-hydroxyvitamin D concentration to the
length of time of illness-free survival were evaluated, including
Vitamin D and Viral Infections
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Weibull functions.
Next, for each of the three observation periods a mean
concentration of 25-hydroxyvitamin D was calculated for each
participant by averaging the concentrations for that participant
from before and after the observation period. Mean concentra-
tions were used rather than concentrations extrapolated to the
date of illness, as (1) it could not be assumed that the change in a
concentration from the beginning to the end of an observation
period was necessarily linear, and (2) concentrations had to be
assigned to the participants who did not become ill.
Participants were stratified into two groups by presence or
absence of an infectious event. An automated partition analysis
[34] to determine what, if any, threshold of serum 25-
hydroxyvitamin D would best discriminate between the two
groups was undertaken for each period of observation and for the
whole study. Parameters obtained from the partition analysis were
compared to those obtained from the initial concentration-
response curve in preparation for a subsequent survival analysis
done to determine the magnitude of risk reduction.
For the survival analysis, participants who experienced an event
(became infected) were assigned the mean vitamin D concentra-
tion for the period in which the event occurred. Participants who
did not experience an event were assigned the minimum mean
concentration taken over the three observation periods. This
approach biased the study towards accepting the null hypothesis of
no difference in event rate between the two groups.
A semi-parametric Cox proportional hazards model [35] was
used to determine if participants stratified by high or low vitamin
D concentrations were less likely to develop an acute viral
respiratory tract infection. Participants who did not complete the
study or who did not experience an event were right-censored to
the time the study ended. Ties for time to event were handled
using the Breslow likelihood. The regression parameters for the
Cox model were estimated by the maximum likelihood method
using JMP 5.0 (SAS, Cary, NC, USA).
The two groups were then examined in an analysis for
differences in sex, age, skin pigmentation, use of herbals and
supplements, use of vitamins other than D, use of vitamin D
supplementation, and receipt of seasonal and 2009 H1N1
influenza vaccines prior to the observation periods. This analysis
involved construction of a non-linear model relating skin
pigmentation (ordinal scale 2=light, 1= intermediate, 0= dark),
gender (nominal F/M), age (yrs), height (in), weight (lbs), and
vitamin D daily dose (IU) to the observed serum vitamin D
concentration obtained at the first blood draw. The preferred
model was chosen based on the explanatory vector of covariates
achieving the lowest Akaike Information Criterion [36].
For each period of observation and for the study duration the
incidences of viral respiratory infections were determined for
participants with 25-hydroxyvitamin D concentrations above and
below the partition value. Comparisons were made, and 95%
confidence intervals for the mean and p values were calculated
using a bootstrap resampling routine (over 100,000 trials) in
MATLAB (The Mathworks, Natick, MA, US) with the resampling
functions package from Resampling Statistics (Resampling Stats,
Inc. Arlington, VA, USA). Observations were then made
regarding the burden of illness by comparing days of viral
respiratory illness per days of observation for participants with 25-
hydroxyvitamin D concentrations above and below the partition
value.
Lastly, the two groups were examined for differences in the
number of participants who developed viral infections associated
with positive virology laboratory studies.
Results
One hundred ninety-eight participants, 85 men and 113
women, with an age range of 20–88, were enrolled in the study.
Skin pigmentation was light (white-yellow) in 154, intermediate
(tan-light brown) in 32, and dark (brown-black) in 12. One
participant withdrew from the study days after the first blood draw
(concentration of 35.7 ng/ml) and two withdrew after the second
blood draw (first period mean concentrations of 9.6 and 25.4 ng/
ml). Thus, 197 were followed for the first period, and 195 for the
remainder of the study.
The study began on September 20, 2009, the date of the first
blood draw, and ended on January 12, 2010, two days after the
last blood draw. An interim analysis of the coded data 2-3 weeks
after the second period of observation caused the investigators to
decide to close the study after the fourth blood draw (the end of the
third period).
Acute infections evaluated
Four patients developed bacterial infections (streptococcal
pharyngitis, two bacterial pneumonias, and diverticulitis). None
of these infections was included in the analysis, as they were not
acute viral respiratory tract infections.
Of the 103 clinical acute respiratory tract infections, 89 (86.4%)
involved physician visits and 14 (13.6%) were documented by
illness diary only. There were 103 acute viral infections diagnosed
clinically in 84 patients during the study, including 62 afebrile
respiratory tract infections, 8 ILI, and 33 laboratory confirmed
infections. Of the 89 clinical viral infections in which virology
studies were performed, 33 (37.1%) had positive results (7 2009
H1N1 influenza, 22 rhinovirus, 3 RSV, and 1 parainfluenza).
25-hydroxyvitamin D concentrations in the study group
The concentrations of 25-hydroxyvitamin D in the participants
were consistent with what has been described in the literature,
including the mean and range of values found; differences based
on sex and skin pigmentation; and, seasonal decline (Table 1). The
results of the initial non-linear model to examine the effects of
population covariates on serum vitamin D concentration suggested
that only skin pigmentation, vitamin D dose, and body mass index
(BMI) were related to serum vitamin D concentrations measured
in the first observation period (Figure 1).
25-hydroxyvitamin D concentrations and viral respiratory
tract infections
For each of the three periods of observation and for the entire
study the partition analysis determined that a vitamin D
concentration of 38 ng/ml best discriminated between groups
that did or did not develop viral infections of the respiratory tract.
This was consistent with the value of 38 ng/ml obtained from the
pharmacodynamic concentration-response curve based on the
initial 25-hydroxyvitamin D concentrations (Figure 2).
The results of the Cox proportional hazard model are presented
in Figure 3. A vitamin D concentration $38 ng/ml approximately
halved the risk for development of an acute viral respiratory tract
infection over the observation period (p,0.0001). The survival
curve depicts events (viral infections). With respect to participants,
83.3% of the 18 who maintained vitamin D concentrations
$38 ng/ml for the entire study survived uninfected, whereas only
55% (99/180) of the other participants survived without infection.
Analyses of the groups with concentrations $38 ng/ml and
,38 ng/ml are delineated in Table 2. There were no differences
due to ingestion of herbals, supplements, or vitamins other than D,
or, due to receipt of seasonal influenza vaccine or 2009 H1N1
Vitamin D and Viral Infections
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higher concentrations of vitamin D were more likely to have
variables that were known from the literature and our non-linear
model to be associated with higher vitamin D concentrations:
lighter skin pigmentation and ingestion of vitamin D, the latter of
which also explained the seemingly apparent difference in the high
and low vitamin D groups based on gender. Only 24/85 (28.2%)
of men were on vitamin D supplements, and only 4/85 (4.7%)
took 1000 IU or more daily; the numbers for the women in the
study were 55/113 (48.7%) and 26/113 (23.0%), respectively.
To examine the burden of illness, the incidence of clinically
diagnosed acute viral respiratory tract infections and percentages
of days ill in participants with 25-hydroxyvitamin D concentra-
tions $38 ng/ml and in those ,38 ng/ml were determined
(Table 3). For each observation period and for the entire study the
incidence of viral respiratory infections and the percentage of days
ill were significantly lower for the group with concentrations of 25-
hydroxyvitamin D$38 ng/ml. Indeed, for the group $38 ng/ml
for the entire study period, the incidence of infection was 2.7 times
lower (p=0.0150). The percentage of days ill in the $38 ng/ml
group compared to the ,38 ng/ml group was 4.9 times lower;
however, a precise multiple could not be determined, as proper
analysis required knowledge of the exact range of illness duration
in the higher group, and, as discussed below, that could not be
determined due to the small number of infections (3) in that group.
Obviously, unless the duration of illness in the group with the
higher 25-hydroxyvitamin D concentrations was longer than in the
other group, the 2.7 fold reduction in incidence would have to
reduce the percentages of days ill by at least that factor in the
higher group.
Duration of illness
For participants with 25-hydroxyvitamin D concentrations
$38 ng/ml, the median duration of illness was 6 days (3
infections, range 2–8 days); for participants with concentrations
,38 ng/ml, the median duration was also 6 days (100 infections,
range 2–27 days). For influenza, the median durations for the high
and low 25-hydroxyvitamin D groups were 2 days (1 infection with
no antivirals given) and 9 days (6 infections, range 2–20 days, with
antivirals in two participants), respectively. The number of
infections in the participants with concentrations $38 ng/ml
was too small to determine if these differences in illness duration
were statistically significant.
Infections with positive virology studies
The numbers of participants with mean concentrations
$38 ng/ml were 32 for the first period, 23 for the second, and
24 for the third. Eighteen participants maintained concentrations
$38 ng/ml for the entire study. Of the 18, 3 developed viral
infections. Of the 180 other participants, 81 developed infections,
and all of the 81 had mean concentrations of vitamin D,38 ng/
ml for the entire study. Of the 18 participants with high vitamin D
concentrations, there was one (5.5%) who developed a laboratory-
confirmed viral infection. Of the other180 participants, there were
32 (17.8%) laboratory-confirmed cases. Due to the small number
of infections in the $38 ng/ml group, the study had a low power
to detect a difference in the incidence of laboratory-confirmed
infections in the two 25-hydroxyvitamin D groups (p=0.0978, by
bootstrap analysis with .100,000 trials).
Table 1. Serum 25-hydroxyvitamin D concentrations over the course of the study by gender and skin pigmentation.
Mean serum 25-hydroxyvitamin D concentrations±standard deviation (range)
1
st blood draw
(09/20/09–09/28/09)
2
nd blood draw
(10/27/09–11/04/09)
3
rd blood draw
(11/30/09–12/06/09)
4
th blood draw
(12/30/09–01/10/10)
All participants N=198 28.460.8 (2.0–73.7) N=197 27.060.8 (2.0–73.0) N=195 24.660.8 (2.0–56.2) N=195 25.660.8 (4.3–60.4)
Female N=113 29.461.1 (2.0–65.6) N=112 28.161.0 (2.0–59.5) N=111 26.561.1 (2.0–56.2) N=111 27.461.1 (4.3–60.4)
Male N=85 27.161.2 (8.2–73.7) N=85 25.561.1 (7.4–73.0) N=84 22.161.0 (5.6–47.2) N=84 23.161.0 (6.7–53.2)
Light pigmentation N=154 30.760.9 (5.4–73.7) N=153 29.060.9 (5.0–73.0) N=152 26.760.9 (2.0–56.2) N=152 27.760.9 (6.0–60.4)
Intermediate
pigmentation
N=32 22.061.1 (10.6–36.1) N=32 20.861.2 (8.6–39.6) N=31 18.361.2 (5.9–33.5) N=31 18.961.2 (6.7–34.1)
Dark pigmentation N=12 15.862.3 (2.0–30.1) N=12 17.463.0 (2.0-32.6) N=12 15.162.3 (2.0–31.3) N=12 16.862.4 (4.3–28.6)
doi:10.1371/journal.pone.0011088.t001
Figure 1. Predicted vs. observed serum 25-hydroxyvitamin D
concentrations. Predicted from the equation [serum vitamin D ng/
ml]=[427.46(1+pigmentation grade)
0.5+(dose IU/day)
0.5]/Body mass
index, where body mass index=(weight lbs)(703)/height inches)
2. See
text for pigmentation grade. The observed concentrations were from
the first observation period. Model parameters were SSE=18755.12;
DFE=197; RMSE=9.75. The error associated with the parameter
estimate was 427.4 +/2 10.4 (SEM) (406.8–448.0) 95% CI.
doi:10.1371/journal.pone.0011088.g001
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This study is the first prospective study that has correlated
serum 25-hydroxyvitamin D concentrations with the incidence of
viral respiratory infections in adult women and men. During 114
days of the fall and winter in a temperate zone a serum
concentration of 25-hydroxyvitamin D of 38 ng/ml or higher
was associated with a two-fold decrease (p,0.0001) in the risk of
developing acute viral infections of the respiratory tract. The effect
size was so large that it was demonstrated with confidence in a
relatively small study. For three consecutive periods and for the
whole study the incidences of infection for the group with 25-
hydroxyvitamin D$38 ng/ml were significantly lower (p values
0.0137, 0.0237, 0.0434, and 0.0150, respectively) than in the
,38 ng/ml group.
Analysis based on the initial 25-hydroxyvitamin D concentra-
tions revealed that the higher the concentration, the greater the
reduction in the incidence of viral infections of the respiratory
tract, with the effect plateauing at concentrations $38 ng/ml. The
findings herein may explain the apparent lack of an effect of
supplementation with vitamin D on reducing the incidence of viral
infections of the respiratory tract in a study done by Li-Ng et al
[37]. In that placebo-controlled interventional study a mean 25-
hydroxyvitamin D concentration of 35 ng/ml was reached in the
treatment group by the end of the study, with 27% still below
30 ng/ml. Had the concentrations reached $38 ng/ml, that study
might have had the power to detect a difference in the treatment
group.
The 25-hydroxyvitamin D concentrations observed in the
present study were consistent with what is known about the
pharmacology of vitamin D in humans. Importantly, increased
melanin content in skin is known to block solar ultraviolet B
radiation required for the first step of synthesis of the vitamin in
the skin. The predicted vitamin D concentration ratio for
individuals with intermediate and dark pigmentation compared
to lightly pigmented individuals in this study was approximately 1/
!2 and 1/!3, respectively, given no additional vitamin D intake
and a similar body mass index. The 18 participants who were able
to maintain 25-hydroxyvitamin D concentration $38 ng/ml for
Figure 2. Length of time to viral infection related to initial serum concentration of 25-hydroxyvitamin D. Shown are the results of the
pharmacodynamic model relating 25-hydroxyvitamin D to length of time before a viral respiratory tract infection. The model equation is Log(time to
event)=b0+b1/(Maximal 25OH-Vit D–serum 25-OH vitamin D+1) calculated using a Weibull loss function. The parameters associated with the
regression are as follows, given with 95% CI and P-values: b0=4.29 (3.50–4.96), ,0.001; b1=38.33 (9.64–76.48), ,0.001; Sigma=0.79 (0.65–0.97),
,0.001. Overall P-value for this model was ,0.0023. Curves are fitted 0.1, 0.5 and 0.9 quantiles as a function of the regressor. The x points represent
individuals who developed viral infections, and the other points represent individuals who did not develop infections and the three who were not
followed until the end of the observation period. For the individuals who developed viral infections (x points) the mean age was 46.9 years; there
were 47% men; 76.5% had light pigmentation, 18.8% intermediate pigmentation, 4.7% dark pigmentation; the mean initial 25-hydroxyvitamin D
concentration was 26.12 ng/ml; and the mean vitamin D supplementation 292.5 IU. For the individuals who did not develop viral infections (the other
points) the mean age was 47.0 years; there were 39.8% men; 78.8% had light pigmentation, 14.2% intermediate pigmentation, 7.0% dark
pigmentation; the mean initial 25-hydroxyvitamin D concentration was 30.03 ng/ml; and the mean vitamin D supplementation 601.4 IU.
doi:10.1371/journal.pone.0011088.g002
Figure 3. Survival without respiratory viral infection over
course of study, stratified by serum 25-hydroxyvitamin D
concentrations. Results of Cox proportional hazard analysis for time
to viral infection, stratified by serum 25-hydroxyvitamin D concentra-
tions. Parameters included 103 events (viral infections), 3 in the
$38 ng/ml group and 100 in the ,38 ng/ml group, and 114 censorings
(15 without infection in the $38 ng/ml group, 99 in the ,38 ng/ml
group, and 3 lost to follow-up). The parameter estimate for 25-
hydroxyvitamin D$38 ng/ml was 20.66 (21.36—0.17) 95% CI and the
risk ratio 0.51 (0.25 to 0.84) 95% CI (p,0.0001).
doi:10.1371/journal.pone.0011088.g003
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on vitamin D supplementation. The data suggested that there is a
non-linear response in dose of vitamin D to serum concentration,
which may be related to suggestions of increased metabolism of
the vitamin in individuals with higher serum vitamin D
concentrations [38]. The study also found an inverse relationship
between body mass index and the serum concentration of the
vitamin, consistent with a higher volume of distribution in
individuals with a higher body mass index due to the high fat
solubility of the vitamin.
There were a number of limitations in this study. First, the
number of ill participants with concentrations $38 ng/ml was too
small to determine whether once infected those participants had a
statistically significant shorter duration of illness. A subsequent
study will be required to determine the durations of illness caused
by specific viruses examined in light of vitamin D concentrations.
It had been expected that there would be many cases of 2009
H1N1 influenza, but the number of cases in the geographic area of
the study was relatively small, and a large percentage of the
subjects had received the 2009 H1N1 vaccine by the second
period of the study, the peak time for influenza in the study’s
location. The virology studies performed used multiplex DFA as
the initial screen and PCR only for selected viruses. Testing did
not include coronavirus or parainfluenza type 4. Nevertheless, the
recovery rate of 37.1% in this study was similar to rates of 39%
[39] and 32.1% [40] reported in the literature in studies of
respiratory tract viral infections in healthy adults in which PCR
tests for more viruses were done. However, in this study the small
number of infections seen in the participants with concentrations
of 25-hydroxyvitamin D$38 ng/ml limited determination of the
effect of 25-hydroxyvitamin D on the incidences of infection
caused by specific viruses; further studies are needed.
The results of this study cannot be assumed to apply to other
settings, but do call for other studies to determine if vitamin D
concentrations have an effect on the following: (1) the incidence of
acute viral respiratory tract infections in individuals under 18 years
of age; (2) the incidence of viral infections affecting other organ
systems and at other times of the year; (3) the course of bacterial,
Table 2. Analysis
a of variables between groups with 25-hydroxyvitamin D concentrations of $38 ng/ml and ,38 ng/ml.
Period 1 (09/20/09–10/
31/09)
Period 2 (11/01/09–11/
30/09)
Period 3 (12/01/09–01/
12/10)
Entire Study (09/20/09–1/
12/10)
Mean 25-hydroxyvitamin D
concentrations (ng/ml)
$38 , 38 P value $38 , 38 P value $38 , 38 P value $38 , 38 P value
Total number in group 32 166 23 175 24 174 18 180
Male/Female 10/22 75/91 1 6/17 79/96 1 3/21 82/92 0.016 2/16 83/97 0.048
Light pigmentation 32 122 0.003 23 131 0.028 24 130 0.028 18 136 0.147
Intermediate pigmentation 0 32 0.031 0 32 0.296 0 32 0.166 0 32 0.487
Dark pigmentation 0 1 21 0 1 21 0 1 21 0 1 2 1
Seasonal influenza vaccine
before period
2 7 1 14 123 1 14 123 1 11 126 1
2009 H1N1 vaccine before
period
01 11 2 2 1 8 7 7 1 6 7 91
Herbals/supplements 9 3 41 9 3 31 8 3 41 6 3 6 1
Vitamins without D 1 71 1611611 6 1
Vitamin D, any dose 20 59 0.060 15 64 0.119 20 59 0.001 13 66 0.048
Vitamin D$1000 IU per day 11 19 0.024 11 19 0.001 13 17 0.001 10 20 0.001
aContingency tables calculating two-tailed p values using Fisher’s exact test with Bonferroni correction for multiple testing were used.
doi:10.1371/journal.pone.0011088.t002
Table 3. Incidence of acute viral respiratory tract infections and number of days ill in groups with 25-hydroxyvitamin D
concentrations of $38 ng/ml and ,38 ng/ml.
Period of observation (dates)
Mean 25-hydroxy
vitamin D
Number partici-
pants with level
Number ill partici-
pants (%) (95% CI) P value
a
Total days
observed Total days ill (%)
Period 1 (09/20/09–10/31/09) $38 ng/ml 32 1 (3.1%) (0.0–9.1) 1240 6 (0.48%)
,38 ng/ml 166 30 (18.1%) (13.2–23.1) p=0.0137 6282 149 (2.4%)
Period 2 (11/01/09–11/30/09) $38 ng/ml 23 1 (4.3%) (0.0–12.5) 690 2 (0.29%)
,38 ng/ml 175 37 (21.1%) (16.2–26.4) p=0.0237 5160 365 (7.1%)
Period 3 (12/01/09–01/12/10) $38 ng/ml 24 1 (4.2%) (0.0–12.0) 1032 8 (0.78%)
,38 ng/ml 174 31 (17.8%) (13.2–22.7) p=0.0434 7353 263 (3.6%)
Entire study (09/20/09–01/12/10) $38 ng/ml 18 3 (16.7%) (4.2–33.3) 1994 16 (0.80%)
,38 ng/ml 180 81 (45%) (38.9–51.1) p=0.0150 19763 777 (3.9%)
aBootstrap p-values and confidence intervals (CI) over 100,000 trials.
doi:10.1371/journal.pone.0011088.t003
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infections which can be worse in groups prone to lower
concentrations of vitamin D, e.g., influenza in pregnant women
and in the obese, tuberculosis in dark skinned individuals, and
fungal infections in dark skinned patients. In addition, careful
intervention studies would be required to evaluate any potential
therapeutic effects of vitamin D in the course of established
infections of any type.
Our data suggest that there is a threshold above which
progressively higher concentrations of vitamin D do not result in
further benefit in reducing the incidence of viral infections of the
respiratory tract. Larger studies might be undertaken examining
different ranges of vitamin D concentrations above 38 ng/ml and
monitoring for any long-term beneficial or adverse effects, given
the widespread presence of vitamin D receptors on so many cell
types.
Importantly, this study demonstrated a beneficial effect of a
serum concentration of vitamin D (38 ng/ml) only slightly higher
than the concentration (30 ng/ml) currently believed to represent
sufficiency [12]. It should be quite safe to supplement one’s diet to
achieve a concentration just above 38 ng/ml; such supplementa-
tion should be done with a diet sufficient in calcium. Our results
need to be replicated in other populations, and since latitude,
season, skin pigmentation, and body mass index all affect serum
vitamin D concentrations, the cost-benefit of supplementation with
or without laboratory testing needs to be determined.
It is estimated that 1 billion people worldwide have vitamin D
concentrations under 30 ng/ml [12], and a much larger number
would be expected to have concentrations under 38 ng/ml, as
found in 81.3% of the participants for entire duration of this study.
The average adult has 2–3 viral respiratory tract infections each
year, resulting in countless physician visits, days lost from school
and work, and enormous direct and indirect costs. A study in 2001
estimated that in the United States alone there were 500 million
non-influenza viral respiratory tract infections each year, resulting
in 189 million school days and 196 million workdays missed by the
ill and their caregivers, with $40 billion dollars in costs [41].
Conclusions
The data in this study suggests that supplementing with vitamin
D to raise the concentrations in the general population to above
38 ng/ml could result in a significant health benefit by reducing
the burden of illness from viral infections, at a minimum from viral
infections of the respiratory tract in healthy adults living in
temperate climates. Our findings may provide direction for and
call for future interventional studies examining the efficacy of
vitamin D supplementation in reducing the incidence and severity
of specific viral infections, including influenza, in the general
population and in specific subpopulations, such as pregnant
women, dark skinned individuals, and the obese.
Acknowledgments
The authors thank Jose Arvi F. Velasco, Zoraida Mercado, Wendy
Calzone, Kathy Mitas, Janice Shelavage, Randy Glover, Rose Olegario,
Christina Curcio, and Kathleen Barry of the Greenwich Hospital Clinical
Laboratory and David Ferguson of Yale New Haven Hospital Clinical
Virology Laboratory for their technical support, Marie Marino-Roux,
Barbara Higgins, Marcia Zack, Marie Dalton, Mary Jacobs, and Linda
Tankoos for help with the phlebotomies, and Deborah Bartalini, Lorraine
Realbuto, and Alison Kemerer for secretarial and administrative
assistance.
Author Contributions
Conceived and designed the experiments: JRS PD ML. Performed the
experiments: JRS RJC JS LAB ML. Analyzed the data: JRS PD RJC JS
LAB ML. Contributed reagents/materials/analysis tools: JRS PD RJC JS
LAB ML. Wrote the paper: JRS PD ML.
References
1. Reichert TA, Simonsen L, Sharma A, Pardo SA, Fedson DS, et al. (2004)
Influenza and the winter increase in mortality in the United States, 1959–1999.
AM J Epidemiol 160: 492–502.
2. Panozzo CA, Fowlkes AL, Anderson LJ (2007) Variation in timing of respiratory
syncytial virus outbreaks: lessons from national surveillance. Pediatr Infect Dis J
26 (11 suppl): S41–45.
3. Gwaltney JM, Jr., Hendley JO, Simon G, Jordan Ws, Jr. (1966) Rhinovirus
infectioninanindustrializedpopulation:I.theoccurrenceofillness.NEnglJMed
275: 1261–1268.
4. Schaffer FL, Soergel ME, Straube DC (1976) Survival of airborne influenza
virus: effects of propagating host, relative humidity, and composition of spray
fluids. Arch Virol 51: 263–273.
5. Hammond G, Raddatz R, Gelskey D (1989) Impact of atmospheric dispersion
and transport of viral aerosols on the epidemiology of influenza. Rev Infect Dis
11: 494–497.
6. Dowell SF (2001) Seasonal variation in host susceptibility and cycles of certain
infectious Diseases. Emerg Infect Dis 7: 369–374.
7. Thacker SB (1986) The persistence of influenza A in human populations.
Epidemiol Rev 8: 129–142.
8. Hope-Simpsom RE (1981) The role of season in the epidemiology of influenza.
J Hyg (Lond) 86: 35–47.
9. McLaughlin M, Raggatt PR, Fairney A, Brown DJ, Lester E, et al. (1974)
Seasonal variations in serum 25-hydroxycholecalciferol in healthy people.
Lancet 1(7857): 536–538.
10. Stamp TC, Round JM (1974) Seasonal changes in human plasma levels of 25-
hydroxyvitamin D. Nature 247: 563–565.
11. Maxwell JD (1994) Seasonal variation in vitamin D. Proc Nutr Soc 53: 533–543.
12. Holick MF (2007) Vitamin D deficiency. N Engl J Med 357: 266–281.
13. Webb AR, Kline L, Holick MF (1988) Influence of season and latitude on the
cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and
Edmonton will not promote vitamin D3 synthesis in human skin. J Clin
Endocrinol Metab 67: 373–378.
14. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, et al. (2006) Toll-like receptor
triggering of a vitamin D-mediated human antimicrobial response. Science 311:
1770–1773.
15. Wang TT, Nestel FP, Bourdeau V, Nagai Q, Wang J, et al. (2004) Cutting edge:
1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene
expression. J Immunol 173: 2909–2912.
16. Gropp R, Frye M, Wagner TO, Bargon J (1999) Epithelial defensins impair
adenoviral infection: implication for adenovirus-mediated gene therapy. Hum
Gene Ther 10: 957–964.
17. Daher KA, Selsted ME, Lehrer RI (1986) Direct inactivation of viruses by
human granulocyte defensins. J Virol 60: 1068–1074.
18. Cantorna MT, Yu S, Bruce D (2008) The paradoxical effects of vitamin D on
type 1 mediated immunity. Mol Aspects Med 29: 369–375.
19. Cheung CY, Poon LL, Lau AS, Luk W, Lau YL, et al. (2002) Induction of
proinflammatory cytokines in human macrophages by influenza (H5N1) viruses:
a mechanism for the unusual severity of disease? Lancet 360: 1831–1837.
20. Khajavi A, Amirhakimi GH (1977) The rachitic lung. Pulmonary findings in 30
infants and children with malnutritional rickets. Clin Pediatr 16: 36–38.
21. Najada AS, Habashneh MS, Khader M (2004) The frequency of nutritional
rickets among hospitalized infants and its relation to respiratory diseases. J Trop
Pediatr 50: 364–368.
22. Martineau AR, Honecker FU, Wilkinson RJ, Griffiths CJ (2007) Vitamin D in
the treatment of pulmonary tuberculosis. J Steroid Biochem Mol Biol 103:
793–798.
23. Grant WB (2008) Variations in vitamin D production could possibly explain the
seasonality of childhood respiratory infections in Hawaii. Pediatr Infect Dis J 27:
853.
24. Ginde AA, Mansbach JM, Camargo CA, Jr. (2009) Association between serum
25-hydroxyvitamin D level and upper respiratory tract infection in the Third
National Health and Nutrition Examination Survey. Arch Intern Med 169:
384–390.
25. Cannell JJ, Vieth R, Umhau JC, Holick MF, Grant WB, et al. (2006) Epidemic
influenza and vitamin D. Epidemiol Infect 134: 1129–1140.
26. Ersfeld DL, Rao DS, Body JJ, Sackrison JL, Jr., Miller AB, et al. (2004)
Analytical and clinical validation of the 25OH vitamin D assay for the Liaison
automated analyzer. Clin Biochem 37: 867–874.
27. Landry ML, Ferguson D (2000) SimulFluor respiratory screen for rapid
detection of multiple respiratory viruses in clinical specimens by immunofluo-
rescence staining. J Clin Microbiol 38: 708–711.
Vitamin D and Viral Infections
PLoS ONE | www.plosone.org 7 June 2010 | Volume 5 | Issue 6 | e1108828. Habib-Bein NF, Beckwith WH, Mayo D, Landry ML (2003) Comparison of
SmartCycler real-time reverse transcription-PCR assay in a public health
laboratory with direct immunofluorescence and cell culture assays in a medical
center for detection of influenza A virus. J Clin Microbiol 41: 3597–3601.
29. Landry ML, Cohen S, Ferguson D (2008) Real-time PCR compared to BINAX
NOW and cytospin-immunofluorescence for detection of influenza in hospital-
ized patients. J Clin Virol 43: 148–151.
30. Lu X, Holloway B, Dare RK, Kuypers J, Yagi S, et al. (2008) Real-time reverse
transcription-PCR assay for comprehensive detection of human rhinoviruses.
J Clin MIcrobiol 46: 533–539.
31. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team, Dawood FS,
Jain S, Finelli L, Shaw MW, et al. (2009) Emergence of a novel swine-origin
influenza A (H1N1) virus in humans. N Engl J Med 360: 2605–2615.
32. Landry ML, Ferguson D (2009) Cytospin-enhanced immunofluorescence and
impact of sample quality on diagnosis of novel swine-origin (H1N1) influenza
virus. J Clin Microbiol. In press.
33. Tor D, Tosteson TD, Buzas JS, Demidenko E, Karagas M (2003) Power and
sample size calculations for generalized regression models with covariate
measurement error. Stat Med 27: 1069–1082.
34. Six sigma, data mining, and the JMP platform (2005). Available: http://www.
northhavengroup.com/pdfs/PartitionInSixSigma.pdf. Accessed 2010 January
12.
35. Cox, DR (1972) Regression models and life tables (with discussion). J Royal
Statistical Soc Series B 34: 187–220.
36. Akaike, H (1974) A new look at the statistical model identification. IEEE Trans
Automat Contr 19: 716–723.
37. Li-Ng M, Aloia JF, Pollack S, Cunha BA, Mikhail M, et al. (2009) A randomized
controlled trial of vitamin D3 supplementation for the prevention of
symptomatic upper respiratory tract infections. Epidemiol Infect 137(10):
1396–1404.
38. Vieth R (2005) The pharmacology of vitamin D, including fortification
strategies. In: Feldman D, Pike JW, Glorieux FH, eds. Vitamin D, 2
nd edn.
London: Elsevier Academic Press. pp 995–1018.
39. Louie JK, Hacker JK, Gonzales R, Mark J, Maselli JH, et al. (2005)
Characterization of viral agents causing acute respiratory infection in a San
Francisco University Medical Center during the influenza season. Clin Infect Dis
41: 822–828.
40. Nolte FS, Marshall DJ, Rasberry C, Schievelbein S, Banks GG, et al. (2007)
MultiCode-PLx system for multiplexed detection of seventeen respiratory
viruses. J Clin Microbiol 45: 2779–2786.
41. Fendrick AM, Monto AS, Nightengale B, Sarnes M (2003) The economic
burden of non-influenza-related viral respiratory tract infection in the United
States. Arch Intern Med 163: 487–494.
Vitamin D and Viral Infections
PLoS ONE | www.plosone.org 8 June 2010 | Volume 5 | Issue 6 | e11088